Login to Your Account

Intercell Stock Plummets on Vaccine Trial Suspension

By Cormac Sheridan

Tuesday, April 12, 2011
Shares in Intercell AG plunged 25 percent Monday after an independent data monitoring committee called for a halt in recruitment for a pivotal Phase II/III trial of a vaccine designed to prevent nosocomial Staphylococcus aureus infection. Although the vaccine, which is partnered with Merck & Co. Inc., did not meet pre-specified futility criteria in an interim analysis, the committee wants additional risk-benefit analyses to be conducted before dosing can resume.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription